Compare MOH & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MOH | ALKS |
|---|---|---|
| Founded | 1980 | 1987 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5B | 8.7B |
| IPO Year | 2002 | 2012 |
| Metric | MOH | ALKS |
|---|---|---|
| Price | $197.37 | $44.18 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 14 |
| Target Price | ★ $167.00 | $43.43 |
| AVG Volume (30 Days) | 437.6K | ★ 1.3M |
| Earning Date | 04-22-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.46 | N/A |
| Revenue | ★ $45,426,000,000.00 | $1,475,899,000.00 |
| Revenue This Year | $2.40 | $24.26 |
| Revenue Next Year | $5.18 | $4.47 |
| P/E Ratio | $137.99 | ★ N/A |
| Revenue Growth | ★ 11.75 | N/A |
| 52 Week Low | $121.06 | $26.99 |
| 52 Week High | $244.89 | $55.67 |
| Indicator | MOH | ALKS |
|---|---|---|
| Relative Strength Index (RSI) | 45.24 | 36.04 |
| Support Level | $196.50 | $36.25 |
| Resistance Level | $204.11 | $51.25 |
| Average True Range (ATR) | 6.39 | 1.44 |
| MACD | 0.08 | -0.15 |
| Stochastic Oscillator | 35.10 | 20.44 |
Molina Healthcare Inc provides medical insurance plans through Medicaid, the individual exchanges, and Medicare. The company operates in four reportable segments consisting of: 1) Medicaid; 2) Medicare; 3) Marketplace; and 4) Other. It manages health benefit risks for more than 5 million people, with more than 85% of those members coming through contracts with state governments for their Medicaid programs. Medicaid contracts in four states-California, New York, Texas, and Washington-account for over half of its enrollees.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.